Zygmont Chester Stanley III 4

What Happened

• Chester S. Zygmont III, CFO of Revelation Biosciences, sold 13,100 shares on Feb 4, 2026 to satisfy tax withholding obligations arising on the vesting of restricted stock awards. The weighted-average price was $1.65, for proceeds of approximately $21,615. The sale was mandatory to cover taxes and not an open-market discretionary sale.

Key Details

• Transaction date: 2026-02-04; Form 4 filed: 2026-02-05 (timely filing).
• Price: weighted average $1.65; shares sold in multiple transactions at prices ranging $1.63–$1.66.
• Amount: 13,100 shares disposed for ~$21,615.
• Transaction code: F — sale to satisfy tax withholding on vesting (mandatory; reporting person did not exercise investment discretion).
• Reverse split: all share counts reflect a 1-for-4 reverse stock split effective Jan 28, 2026.
• Holdings notes in filing: some shares are held by The Zygmont Family Trust and by Czeslaw Capital Fund, LLC (he is trustee/sole manager).
• Shares owned after the transaction are not specified in the information provided here.

Context

• This was a sell-to-cover (tax withholding) related to restricted stock vesting, not a voluntary open-market sale; such transactions are routine and reflect tax obligations rather than a directional bet on the stock.
• The filing discloses the weighted-average price and a range; the reporter offered to provide exact per-trade details on request.